JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

A Clinical Perspective of Tobacco Cessation, Nicotine Neurobiology, and Pharmacotherapeutic Interventions

Chandrika C*, Shekar H S, Gopinatha K

Department of Pharmacy Practice, Visveswarapura Institute of Pharmaceutical Sciences, Bangalore, Karnataka, India

Publication history: Received on 26th April 2026; Revised on 28th May 2026; Accepted on 29th May 2026

Article DOI: 10.69613/cbmh5631

Abstract: Tobacco consumption is a severe public health crisis in India, accounting for substantial morbidity and premature mortality through chronic obstructive pulmonary disease, cardiovascular pathologies, and respiratory malignancies. The dual burden of smoked tobacco products such as cigarettes and beedis and smokeless variants including gutkha, khaini, and paan masala creates distinct clinical challenges across diverse demographics. Nicotine addiction is driven by its high affinity for neuronal nicotinic acetylcholine receptors in the ventral tegmental area, initiating mesolimbic dopamine release within the nucleus accumbens to reinforce repetitive administration. Hepatic biotransformation, driven largely by cytochrome P450 2A6 and 2B6 enzymatic pathways, converts nicotine to cotinine and trans-3'-hydroxycotinine, dictating systemic clearance and withdrawal dynamics. Chronic exposure alters neuroreceptor density, precipitating severe physical withdrawal symptoms upon cessation. Clinical interventions combining high-dose nicotine replacement therapy utilizing transdermal patches, chewing gums, lozenges, or nasal sprays with structured non-pharmacological counseling significantly elevate abstinence rates. Patients with underlying chronic obstructive pulmonary disease comprise the vulnerable population with heightened physical dependence, requiring intensified pharmacotherapy alongside frequent clinical monitoring to prevent relapse. Integrating trained clinical pharmacists into healthcare systems optimizes dependence scoring via the Fagerström Test for Nicotine Dependence, facilitates individualized dosage titration, and enhances medication adherence through continuous behavioral support. Multimodal cessation interventions that unify pharmacological reinforcement attenuation with clinical care remain essential to reduce tobacco-related disease burdens.

Keywords: Tobacco cessation; Nicotine dependence; Chronic obstructive pulmonary disease; Nicotine replacement therapy; Clinical pharmacy practice.

1. Introduction

Tobacco consumption is the primary cause of preventable mortality globally, precipitating severe economic and healthcare burdens across diverse populations [1]. Worldwide estimates indicate that tobacco consumption accounts for approximately six million deaths annually, with nearly 890,000 fatalities resulting from passive secondhand smoke exposure [2, 3]. Global epidemiological surveys identify over 1.1 billion active tobacco consumers, the vast majority residing in low- and middle-income nations where disease burdens are disproportionately accentuated [4]. Within India, tobacco usage poses an unprecedented public health challenge, directly contributing to over six million deaths and projected to cause more than 1.5 million annual fatalities in the near future [2, 5].

The tobacco consumption across the Indian subcontinent exhibits marked geographic, gender, and socio-economic variation. National surveys, such as the Global Adult Tobacco Survey, indicate an overall adult prevalence of approximately 31%, with northern states exhibiting consumption rates reaching 44% in males and 6% in females [4, 6]. India ranks as the third-largest consumer and second-largest producer of tobacco globally [5]. Unlike patterns observed in Western nations, smokeless tobacco consumption in India shows high prevalence among female demographics, creating distinct clinical disease presentations and requiring tailored public health measures [6].

The diversity of tobacco delivery formats in India significantly complicates clinical cessation paradigms. Smoked tobacco encompasses traditional commercial cigarettes as well as beedis, which consist of raw unprocessed tobacco hand-rolled in dried tendu (*Diospyros melanoxylon*) or temburni leaves [7]. Beedis yield higher concentrations of nicotine, carbon monoxide, and tar per gram of tobacco than conventional cigarettes, heightening systemic toxicity [8]. Smokeless tobacco formats include gutkha and paan masala (aerated tobacco blended with slaked lime, areca nut, and aromatic spices), khaini (sun-dried tobacco mixed with calcium hydroxide), and mishri (roasted tobacco powder applied directly to gingival tissues) [7, 9]. These varied formulations contain

* Corresponding author: Chandrika C

thousands of xenobiotic compounds, including at least 69 established human carcinogens such as tobacco-specific nitrosamines, polycyclic aromatic hydrocarbons, and heavy metals [8, 10]. Table 1 summarizes the physical characteristics, delivery mechanisms, and major chemical toxicities associated with common smoked and smokeless tobacco formulations in India.

Table 1. Common Smoked and Smokeless Tobacco Formulations in India

Tobacco Category	Product	Composition	Primary Route of Absorption	Major Chemical Constituents & Toxins
Smoked Tobacco	Commercial Cigarette	Processed cured tobacco leaves with added humectants and filters	Pulmonary alveoli (rapid systemic inhalation)	Nicotine, Carbon monoxide, Tar, Benzo[a]pyrene, Polycyclic aromatic hydrocarbons
Smoked Tobacco	Beedi	Raw, sun-dried tobacco wrapped in tendu or temburni leaf	Pulmonary alveoli (high-yield inhalation)	Elevated Nicotine, High Carbon monoxide, Phenols, Tobacco-specific nitrosamines (NNK, NNN)
Smokeless Tobacco	Gutkha / Paan Masala	Coarse tobacco, slaked lime, crushed areca nut, and paraffin wax	Oral mucosal membrane	Alkaloids (Arecoline), Slaked lime ($Ca(OH)_2$), Heavy metals (Lead, Cadmium), Nitrosamines
Smokeless Tobacco	Khaini	Sun-dried shredded tobacco mixed manually with slaked lime	Buccal mucosal membrane	High un-ionized Nicotine (facilitated by alkaline pH), Tobacco-specific nitrosamines, Polonium-210
Smokeless Tobacco	Mishri	Pyrolyzed/roasted tobacco powder applied directly to gingiva	Oral mucosal membrane	Polycyclic aromatic hydrocarbons, Pyrolysis derivatives, Nitrosamines

2. Mechanisms of Nicotine Dependence and Metabolism

2.1. Pharmacodynamics and Neuronal Receptors

Nicotine, chemically identified as 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine, serves as the principal psychoactive phytoconstituent responsible for the addictive properties of tobacco [11]. Upon inhalation or mucosal absorption, nicotine rapidly enters the systemic circulation and crosses the blood-brain barrier within several seconds [12]. Within the central nervous system, nicotine functions as a full agonist at neuronal nicotinic acetylcholine receptors (nAChRs), which exist as pentameric ligand-gated ion channels composed of α (α2–α10) and β (β2–β4) subunits [13]. The dominant receptor subtype mediating addictive reinforcement is the high-affinity heteropentameric α4β2 nAChR located within the ventral tegmental area [11, 14].

2.2. Mesolimbic Dopaminergic Pathways and Reward Mechanisms

Agonist binding to α4β2 nAChRs in the ventral tegmental area triggers channel opening, extracellular cation influx, and localized membrane depolarization [13]. This electrophysiological activation stimulates burst firing of dopaminergic projection neurons terminating in the nucleus accumbens, releasing substantial quantities of dopamine into the synaptic cleft [11, 15]. The acute elevation of dopamine within the mesolimbic reward system produces transient euphoric effects, heightened alertness, and positive neurobehavioral reinforcement [16]. Repeated nicotine exposure induces neuroadaptations characterized by the upregulation and desensitization of nAChR complexes [12]. Abrupt cessation lowers extracellular dopamine concentrations below baseline, precipitating physical withdrawal manifestations including intense craving, affective irritability, anxiety, cognitive impairment, insomnia, and hyperphagia [17].

2.3. Pharmacokinetics and Hepatic Enzymatic Metabolism

Following absorption, nicotine undergoes extensive hepatic biotransformation, primarily via microsomal oxidation [18]. Approximately 70% to 80% of absorbed nicotine is converted into its primary inactive metabolite, cotinine, through a two-step enzymatic reaction mediated by cytochrome P450 2A6 (CYP2A6) and cytosolic aldehyde oxidase [19]. Cotinine subsequently undergoes secondary oxidation by CYP2A6 to form trans-3'-hydroxycotinine, which constitutes the major urinary nicotine metabolite [20]. Minor metabolic pathways include N-demethylation to nornicotine via CYP2A6 and CYP2B6 isoforms, alongside N-glucuronidation via UDP-glucuronosyltransferase enzymes [19, 21]. The systemic half-life of nicotine averages two hours, whereas cotinine exhibits a half-life of 16 to 20 hours, rendering cotinine a stable biomarker for quantifying recent tobacco exposure in plasma, saliva, or urine [18, 22]. Interindividual variations in CYP2A6 catalytic activity, driven by genetic polymorphisms, directly influence nicotine clearance rates, withdrawal severity, and daily tobacco consumption levels [20].



Figure 1. Neurobiological Pathways of Nicotine Dependence and Physical Withdrawal.
Inhaled or mucosal nicotine rapidly crosses the blood-brain barrier to bind heteropentameric α4β2 nicotinic acetylcholine receptors (α4β2 nAChRs) in the ventral tegmental area (VTA), triggering mesolimbic dopamine release within the nucleus accumbens (NAc). Chronic exposure induces receptor upregulation and neuroadaptation, leading to severe neurochemical dopamine deficits and physical withdrawal upon abrupt abstinence

3. Pathophysiological Impact on Respiratory and Chronic Diseases

3.1. Tobacco Smoke Composition and Carcinogenesis

Inhaled tobacco smoke constitutes a complex aerosol containing over 7,000 distinct chemicals, including reactive oxygen species, volatile organic compounds, and heavy metal ions [8]. Carcinogenic elements such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), N'-nitrosonornicotine (NNN), and benzo[a]pyrene induce direct DNA adduct formation, causing genomic mutations in key tumor suppressor genes such as *TP53* and proto-oncogenes such as *KRAS* [10, 23]. These genetic alterations disrupt cellular apoptotic pathways, drive uncontrolled cell proliferation, and initiate malignant transformation within the bronchial epithelium, establishing active smoking as the primary cause of bronchogenic carcinoma [23, 24].

3.2. Pulmonary Pathophysiology and Chronic Obstructive Pulmonary Disease

Cigarette smoking is the paramount etiology in the pathogenesis of chronic obstructive pulmonary disease (COPD), a progressive disease entity characterized by chronic bronchitis and emphysematous tissue destruction [25]. Inhalation of noxious tobacco constituents triggers sustained inflammatory cascades within small airways and lung parenchyma [26]. Macrophages and neutrophils recruited to the pulmonary interstitium release proteolytic enzymes, predominantly matrix metalloproteinases and neutrophil elastase, overwhelming endogenous antiprotease defenses such as α1-antitrypsin [27]. Concurrent oxidative stress inactivates antiproteases and damages alveolar capillary units, causing irreversible loss of elastic recoil, structural wall collapse, and accelerated decline in forced expiratory volume in one second (FEV1) [25, 28].



Figure 2. Pathophysiological mechanism linking inhaled tobacco toxicants to progressive chronic obstructive pulmonary disease (COPD)

Chronic inhalation triggers ongoing recruitment of inflammatory cells (macrophages and neutrophils) into the lung parenchyma. The excess secretion of proteolytic enzymes overpowers antiprotease protection (a1-antitrypsin), causing elastolytic alveolar destruction, small airway remodeling, and an accelerated decline in forced expiratory volume in 1 second (FEV1).

3.3. Gender-Specific Vulnerabilities and Symptomatology

Female tobacco users exhibit amplified susceptibility to the toxic effects of tobacco smoke relative to male counterparts with equivalent pack-year histories [29]. Epidemiological data show that female smokers experience greater declines in lung function, earlier onset of fixed airflow limitation, and elevated hospitalization rates for acute COPD exacerbations [29, 30]. Proposed physiological mechanisms include differential cytochrome P450 expression, anatomical differences in airway caliber, and estrogen-mediated modulation of oxidative stress pathways [29]. Across both sexes, chronic tobacco exposure produces persistent upper and lower respiratory symptoms, including productive cough, wheezing, exertional dyspnea, and recurrent chest infections [31]. Complete tobacco cessation is the sole intervention to arrest the accelerated loss of lung function and reduce long-term mortality in respiratory patients [28, 32].

4. Clinical Assessment and Therapeutic Interventions

5. 4.1 Quantitative Diagnostics and Nicotine Dependence Scale

Systematic identification and quantification of nicotine dependence are the foundational prerequisites for successful clinical cessation management [33]. The Fagerström Test for Nicotine Dependence (FTND) serves as the primary psychometric instrument utilized globally to evaluate physical dependence severity [34]. The FTND evaluates six key behavioral variables, including time to the first morning tobacco use, difficulty refraining from use in prohibited areas, and daily consumption quantity [34, 35]. Scores ranging from 0 to 3 indicate low dependence, 4 to 6 moderate dependence, and 7 to 10 high physical dependence [34]. Diagnostic assessment can be supplemented by objective biomarker testing, such as exhaled carbon monoxide measurement in parts per million (ppm) or quantitative immunoassay of salivary or urinary cotinine concentrations, providing verifiable baseline data and monitoring adherence during follow-up [22, 36].



Figure 3. Clinical decision flowchart for pharmacist-managed tobacco cessation

Upon documenting tobacco consumption, physical nicotine dependence is systematically quantified using the Fagerström Test for Nicotine Dependence (FTND). Patients ready to attempt cessation receive combination pharmacotherapy (nicotine replacement therapy) integrated with the behavioral 5 A's model (Ask, Advise, Assess, Assist, Arrange). Patients ambivalent or unready to quit undergo motivational interviewing based on the 5 R's framework (Relevance, Risks, Rewards, Roadblocks, Repetition) with planned future re-evaluation.

5.1. Pharmacotherapy and Nicotine Replacement Protocols

Pharmacotherapeutic management of tobacco dependence focuses on attenuating physical withdrawal symptoms and reducing acute cravings [37]. Nicotine Replacement Therapy (NRT) formulations deliver systemic nicotine without exposing the patient to toxic combustion products [38]. Transdermal nicotine patches provide continuous background systemic venous absorption over 16 to 24 hours, stabilizing plasma concentrations to suppress baseline withdrawal [38, 39]. Transmucosal delivery forms including nicotine chewing gums, oral lozenges, sublingual tablets, and nasal sprays achieve faster plasma peak levels, permitting rapid self-

administration during acute craving episodes [38, 40]. Combining continuous transdermal patches with rapid-acting oral formulations yields superior long-term abstinence rates compared to monotherapy, particularly in highly dependent individuals [39, 41]. Non-nicotine oral pharmacotherapies, such as bupropion sustained-release and varenicline tartrate (a selective α4β2 nAChR partial agonist), offer effective non-NRT alternatives or adjuncts [33, 37]. Table 2 describes the list of available nicotine replacement therapy formulations, showing their dosing, pharmacokinetic parameters, and distinct clinical considerations.

Table 2. List of Available Nicotine Replacement Therapy

NRT Dosage Form	Standard Dosing Paradigm	Pharmacokinetic Onset (T_{max})	Peak Plasma Level (C_{max})	Clinical Application & Advantage
Transdermal Patch	7 mg, 14 mg, 21 mg per 24 hours (Step-down over 8–12 weeks)	Slow (2 to 9 hours)	Continuous baseline level (10–25 ng/mL)	Steady systemic delivery; controls background baseline withdrawal symptoms.
Chewing Gum	2 mg or 4 mg per piece (Chew-and-park method every 1–2 hours)	Moderate (30 minutes)	Rapid spike (5–10 ng/mL per piece)	Breakthrough craving control; allows patient-controlled acute dosing.
Oral Lozenge	2 mg or 4 mg (Dissolved slowly between cheek and gum)	Moderate (30 minutes)	Rapid spike (7–12 ng/mL)	Ideal for patients unable to chew gum; faster nicotine bioavailability.
Nasal Spray	0.5 mg per spray (1–2 sprays per hour; max 40 mg/day)	Rapid (5–10 minutes)	Sharp arterial-like peak (5–12 ng/mL)	Fastest systemic onset among NRTs; effectively blunts acute severe urges.

5.2. Behavioral Interventions

Optimal tobacco cessation outcomes require integrating pharmacotherapy with structured non-pharmacological behavioral support [33, 42]. The 5 A's framework Ask, Advise, Assess, Assist, and Arrange provides a systematic behavioral protocol for healthcare encounters [33]. For patients showing ambivalence toward quitting, motivational interviewing structured around the 5 R's Relevance, Risks, Rewards, Roadblocks, and Repetition enhances internal motivation [33].

Table 3. Clinical Pharmacy Interventions for Tobacco Dependence Treatment

Behavioral Interventions	Phase / Stage	Clinical Pharmacist Action	Operational Clinical Target
5 A's Models	Ask	Systematically document tobacco use status for every patient at admission or outpatient intake.	Establish comprehensive baseline tobacco registries.
	Advise	Provide direct, non-judgmental advice on the clinical benefits of immediate tobacco cessation.	Heighten patient awareness regarding health risks.
	Assess	Evaluate degree of dependence using FTND and determine willingness to make a quit attempt.	Categorize physical dependence severity (0–10).
	Assist	Prescribe/recommend NRT regimens and deliver brief behavioral counseling tailored to patient needs.	Formulate individualized pharmacotherapeutic plans.
	Arrange	Schedule regular follow-up contacts during the initial 2–4 weeks post-quit date.	Prevent premature relapse and manage side effects.
5 R's Models	Relevance	Encourage the patient to identify personal reasons why quitting tobacco is clinically important.	Link cessation to personal health goals and family.
	Risks	Discuss acute, long-term, and environmental health risks specific to the patient's medical condition.	Frame specific complications (e.g., COPD exacerbation).
	Rewards	Highlight tangible clinical, financial, and personal benefits of successful long-term cessation.	Emphasize improved lung function (FEV1) and savings.
	Roadblocks	Identify potential barriers to quitting (e.g., stress, cohabitants who smoke, severe withdrawal).	Formulate proactive coping strategies.
	Repetition	Re-engage unready patients at subsequent encounters with motivational interviewing.	Build readiness over time through regular contact.

Clinical pharmacists possess specialized training in pharmacology, dosage individualization, and longitudinal patient monitoring, positioning them to manage tobacco cessation [43]. Within primary and tertiary care settings, clinical pharmacists systematically screen patients for tobacco use, administer the FTND, recommend and titrate appropriate NRT regimens, monitor for drug-drug interactions, and provide structured relapse prevention counseling [43, 44]. Pharmacist-led clinical management significantly

improves patient compliance, mitigates adverse events, and improves successful quit rates among high-risk populations, including individuals with diagnosed COPD [44, 45]. Table 3 provides the clinical pharmacy interventions across the 5 A's and 5 R's models, detailing specific clinical actions performed during patient consultations.

6. Conclusion

Tobacco addiction is a major public health challenge, driving extensive morbidity and mortality through respiratory, cardiovascular, and oncological diseases. The neurobiological mechanisms of nicotine action at α4β2 neuronal receptors and its hepatic metabolism provides a clear rationale for clinical interventions. Quantitative dependence diagnostic methods like the Fagerström scale with combination nicotine replacement therapy and structured behavioral counseling provides an effective means to overcome addiction. Clinical pharmacists play an essential role by assessing dependence, tailoring pharmacotherapy, providing ongoing counseling, and managing long-term care. Clinical pharmacy-led tobacco cessation programs within healthcare delivery systems helps in reducing tobacco dependence and lowers the burden of tobacco-related disease.

References

[1] Ezzati M, Lopez AD. Regional, disease-specific patterns of smoking-attributable mortality in 2000. Tob Control. 2004;13(4):388-395.

[2] World Health Organization. WHO report on the global tobacco epidemic, 2019: Offer help to quit tobacco use. Geneva: World Health Organization; 2019.

[3] Reitsma MB, Fullman N, Ng M, Salama JS, Abajobir A, Abate KH, et al. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet. 2017;389(10082):1885-1906.

[4] Tata Institute of Social Sciences (TISS), Ministry of Health and Family Welfare, Government of India. Global Adult Tobacco Survey GATS 2 India 2016-17. Mumbai: TISS; 2017.

[5] Jha P, Jacob B, Gajalakshmi V, Gupta PC, Dhingra N, Kumar R, et al. A nationally representative case-control study of smoking and death in India. N Engl J Med. 2008;358(11):1137-1147.

[6] Rani M, Bonu S, Jha P, Nguyen SN, Jamison L. Tobacco use in India: prevalence and predictors of smoking and chewing in a national cross-sectional household survey. Tob Control. 2003;12(4):e4.

[7] Gupta PC, Ray CS. Smokeless tobacco and health in India and South Asia. Respirology. 2003;8(4):419-431.

[8] Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst. 2002;94(14):1044-1057.

[9] Boffetta P, Hecht S, Gray N, Gupta P, Straif K. Smokeless tobacco and cancer. Lancet Oncol. 2008;9(7):667-675.

[10] Hecht SS. Lung carcinogenesis by tobacco smoke. Int J Cancer. 2012;131(12):2724-2732.

[11] Benowitz NL. Nicotine addiction. N Engl J Med. 2010;362(24):2295-2303.

[12] Dani JA, De Biasi M. Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav. 2001;70(4):439-446.

[13] Changeux JP. Nicotinic receptors and nicotine addiction. C R Biol. 2010;333(4):359-366.

[14] Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C, et al. Nicotine activation of alpha4 nicotinic receptors is sufficient for reward, tolerance, and sensitisation. Science. 2004;306(5698):1029-1032.

[15] Balfour DJ. The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus accumbens. Nicotine Tob Res. 2004;6(6):899-912.

[16] Di Chiara G. Role of dopamine in the behavioural actions of nicotine in animals. Eur J Pharmacol. 2000;393(1-3):295-314.

[17] Hughes JR. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res. 2007;9(3):315-327.

[18] Benowitz NL, Hukkanen J, Jacob P 3rd. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol. 2009;(192):29-60.

[19] Hukkanen J, Jacob P 3rd, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005;57(1):79-115.

[20] Malaiyandi L, Sellers EM, Tyndale RF. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Pharmacogenomics J. 2005;5(1):57-65.

[21] Yamanaka H, Nakajima M, Nishimura K, Yoshida R, Fukami T, Katoh M, et al. Metabolic profile of nicotine in human liver microsomes. Drug Metab Dispos. 2005;33(4):511-517.

[22] Benowitz NL. Cotinine as a biomarker of environmental tobacco smoke exposure. Epidemiol Rev. 1996;18(2):188-204.

[23] Pfeifer GP, Denissenko MF, Tretyakova M, Tretyakov A, Akopyan O, Tang MS. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 2002;21(48):7435-7451.

[24] Alexandrov LB, Ju YS, Haase K, Van Loo P, Martincorena I, Nik-Zainal S, et al. Mutational signatures associated with tobacco smoking in human cancer. Science. 2016;354(6312):618-622.

[25] Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med. 2000;343(4):269-278.

[26] Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645-2653.

[27] Tetley TD. Inflammatory cells and chronic obstructive pulmonary disease. Curr Pharm Des. 2005;11(10):1285-1296.

[28] Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142(4):233-239.

[29] Gan WQ, Man SF, Postma DS, Camp P, Sin DD. Female gender increases the risk for chronic obstructive pulmonary disease in small-airway disease. Thorax. 2006;61(5):416-422.

[30] Aryal S, Diaz-Guzman E, Mannino DM. COPD and gender differences: an update. Transl Res. 2013;162(4):208-218.

[31] Cerveri I, Accordini S, Corsico A, Zoia MC, Carrozzi L, Cazzoletti L, et al. Chronic cough and phlegm in young adults. Eur Respir J. 2003;22(3):413-417.

[32] Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease: the Lung Health Study. Am J Respir Crit Care Med. 2000;161(2):381-390.

[33] Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service; 2008.

[34] Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86(9):1119-1127.

[35] Fagerström K. Determinants of tobacco dependence and implications for the day-to-day treatment of smoker. Tob Control. 2002;11(Suppl 2):ii39-ii45.

[36] SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine Tob Res. 2002;4(2):149-159.

[37] Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;2013(5):CD009329.

[38] Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11(11):CD000146.

[39] Sweeney CT, Fant RV, Fagerstrom KO, McGovern JF, Henningfield JE. Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability. CNS Drugs. 2001;15(6):453-467.

[40] West R, Shiffman S. Effect of oral nicotine dosing forms on cigarette withdrawal symptoms and craving: a systematic review. Psychopharmacology. 2001;155(2):115-122.

[41] Shah SD, Wilken LA, Winkler SR, Lin SJ. Systematic review and meta-analysis of combination therapy for smoking cessation. J Am Pharm Assoc (2003). 2008;48(5):659-665.

[42] Stead LF, Buitrago D, Preciado N, Sanchez G, Hartmann-Boyce J, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2013;2013(5):CD000165.

[43] Saba M, Diep J, Saini B, Armour CL. Public health role of community pharmacists in smoking cessation methods. Int J Clin Pharm. 2014;36(2):240-252.

[44] Carson-Chahhoud KV, Hebden Lindsay R, Maguire T, Chan R, van der Molen T. Community pharmacy-led interventions for smoking cessation. Cochrane Database Syst Rev. 2019;2019(10):CD003698.

[45] van der Molen T, van Boven JF, Maguire T, Goyder EC, Postma DS. Optimizing identification and management of COPD patients reviewing the role of the community pharmacist. Br J Clin Pharmacol. 2017;83(1):192-201.